期刊文献+

葡萄糖酸钙与万汶对预防卵巢过度刺激综合征的随机对照研究 被引量:2

Voluven versus Calcium Gluconate for the prevention of ovarian hyperstimulation syndrome:aprospective,randomized controlled study
原文传递
导出
摘要 目的探讨葡萄糖酸钙与万汶在预防体外受精-胚胎移植时促排卵产生的卵巢过度刺激综合征(OHSS)中的作用。方法应用前瞻性随机对照研究将OHSS高危患者分为三组,Ⅰ组50例,Ⅱ组51例,于取卵后分别静点10%葡萄糖酸钙10ml、6%万汶1 000ml作为预防性治疗组,Ⅲ组49例未予任何治疗作为对照组,取卵日起连续用药3d,监测用药前后卵巢大小与血常规,观察各组治疗后的可移植胚胎人数、临床妊娠率及发生重度OHSS的患者比率。结果三组患者可移植胚胎人数差异无统计学意义(P>0.05)。万汶治疗前后卵巢体积增大最小,但差异无统计学意义(P>0.05);HCT增加同样最低,与其他两组比较差异有统计学意义(P<0.05)。三组重度OHSS发病率差异无统计学意义(P>0.05),早发型OHSS发病率三组相近,晚发型OHSS均发生于葡萄糖酸钙组。妊娠率三组间差异有统计学意义(P<0.05),在葡萄糖酸钙组最高,万汶组最低。结论高反应患者预防性应用葡萄糖酸钙与万汶并未减少重度OHSS的发生,但是万汶的应用降低了高反应患者的血液浓缩状态,葡萄糖酸钙的应用可能促进了妊娠率的提高。 Objective To assess the effectiveness of 6 % hydroxyethyle starch (Voluven) and calcium glu- conate at the time of oocyte retrieval for preventing severe OHSS at high -- risk patients in an in--vitro fertilization programme. Methods This is a prospective, randomized and placebo -- controlled study. There were 50 patients in calcium gluconate group , 51 in voluven group and 49 in control group. The ovarian size was measured on the day of hCG administration, oocyte collection and embryo transfer. The blood routine was measured on the same days. The number of transferred patients, embryos transferred, pregnancies and severe OHSS patients were observed in the study. Results No significantly difference of the number of transferred patients , embryos transferred , and severe OHSS patients was found in the three groups (P~ 0.05). The number of pregnant patients was highest in calcium gluconate group, lowest in voluven group, there were significantly difference in the three groups (P^0.05). Although there was no significant difference of the ovarian enlargement in the three groups on the day of embryo transfer and the day of hCG administration (P^0. 05) , it was lower in voluven group than that in the other groups. And the increasing of HCT was also the lowest in voluven group, there were significantly difference in the three groups (P^0. 05). The number of early severe OHSS patients was similar in the three groups, but three patients of late severe OHSS were all in calcium gluconate group. Conclusion Administration of voluven and calcium gluconate did not avoid the development of severe OHSS in high - risk patients, but infused treatment of voluven may help to decrease pachyhemia, calcium gluconate maybe help to increase pregnancy.
出处 《中国妇产科临床杂志》 CSCD 北大核心 2015年第3期233-236,共4页 Chinese Journal of Clinical Obstetrics and Gynecology
关键词 卵巢过度刺激综合征 万汶 葡萄糖酸钙 预防 voluven calcium gluconate ovarian hyperstimulation syndrome prevention
  • 相关文献

参考文献9

  • 1Humaidan P, Quartarolo J, Evangelos G, et al. Preventing ovarian hyperstimulation syndrome., guidance for the clini- cian. Fertil Sterii, 2010, 94: 389-400.
  • 2Yakovenko SA, Sivozhelezov VS, Zorina IV, et al. Preven- tion of OHSS by intravenous calcium. Hum Reprod, 2009, 24 (suppl 1) : 61.
  • 3Herr D, Duncan WC, Hack G, et al. Regulated expression of the renin - angiotensin - system in human granulosa lutein cells., angiotensin II increases VEGF expression but its syn- thesis is reduced by hCG. Arch Gynecol Obstet, 2010, 281: 409 - 416.
  • 4Beierwaltes WH. The role of calcium in the regulation of renin secretion. Am J Physiol Renal Physiol, 2010, 298:F1 - 11.
  • 5Gurgan T, Demirol A, Guven S, et al. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimu- lation syndrome for patients with polycystic ovarian syn- drome. Fertil Steril, 2011, 96: 53-57.
  • 6Kitsou C, Kosmas I, Lazaros L, et at. Ovarian hyperstimula- tion syndrome inhibition by targeting VEGF, COX - 2 and Calcium pathways., a preclinical randomized study. Gynecol Endocrinol, 2014, 30:587 - 592.
  • 7Tong XM, Lin XN, Song T, et al. Calcium-binding protein SLOOP is highl.y expressed during the implantation window in human endometriun~ Fertil Steril, 2010, 94: 1510- 1518.
  • 8Choi KC, An BS, Yang H, et al. Regulation and molecular mechanisms of calcium transport genes., do they play a role in cal- cium transport in the uterine endometrium? J Physio Pharma, 2011, 62: 499-504.
  • 9范燕宏,乔杰,陈贵安,陈新娜,王海燕,马彩虹,刘平.贺斯与白蛋白对预防重度卵巢过度刺激综合征的对比性研究[J].中国妇产科临床杂志,2007,8(4):245-248. 被引量:8

二级参考文献11

  • 1[1]Golan A,Ron-el R,Herman A,et al.Ovarian hyperstimulation syndrome:an update review.Obstet Gynecol Survey,1989,44:430-440.
  • 2[2]Asch RH,Ivery G,Goldsman M,et al.The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome.Hum Reprod,1993,8:1015-1020.
  • 3[3]Shoham Z,Weissman A,Barash A,et al,Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program.a prospective,randomized,placebo-controlled study.Fertil Steril,1994,62:137-142.
  • 4[4]Chen CD,Wu MY,Yang JH,et al,Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.Fertil Steril,1997,68:287-291.
  • 5[5]Ng E,Leader A,Claman P,et al,Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme.Hum Reprod,1995,10:807-810.
  • 6[7]Graf MA,Fischer R,Naether OGJ,et al.Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyethyle starch solution in an in-vitro fertilization programme.Hum Reprod,1997,12:2599-2602.
  • 7[8]Konig E,Bussen S,Sutterlin M,et al.Proghylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients:a prospective,randomized,double-blind and placebo-controlled study.Hum Reprod,1998,13:2421-2424.
  • 8[9]Gokmen O,Ugur M,Ekin M,et al.Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme:a prospective randomized placebo controlled study.Euro J Obstec Gynec and Reprod Biolo,2001,96:187-192.
  • 9[10]The practice committec of the American socrtty for reprodictive medicine.Ovarian hyperstimulation syndrome.Fertil Steril,2006,86:178-183.
  • 10[11]Galushka SV,Nazarov BF,Vlasenko AV.Use of the solutions of hydroxyethyl starch and reamberin in the combined treatment of severe gestosis.Anesteziologiia i reanimatologiia,2004,6:44-47.

共引文献7

同被引文献46

  • 1陈洁.卵巢过度刺激综合征38例临床治疗观察[J].中外医疗,2008,27(24):35-36. 被引量:2
  • 2谈勇.卵巢过度刺激综合征的辨证论治[J].江苏中医药,2006,27(3):13-14. 被引量:19
  • 3刘凤云,吴先哲,张敏,郭广洲,黄志欣.益肾利水方对卵巢过度刺激综合征患者血管通透性的影响[J].中医杂志,2007,48(11):989-991. 被引量:15
  • 4佟丽丽,满玉晶,吴效科.中药辅助治疗重度卵巢过度刺激综合征1例[J].中国医药导报,2007,4(12X):236-237. 被引量:8
  • 5Nastri CO, Ferriani RA, Rocha IA, et al. Ovarian hyperstimulation syndrome: pathophysiology and prevention. 1 Assist Reprod Genet, 2010, 27(2-3): 121-128.
  • 6Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update, 2003, 9(1): 77-96.
  • 7McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet, 1994, 344(8917): 235-136.
  • 8Morris RS, Wong IL, Kirkman E, et al. Inhibition of ovarian- derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod, 1995, 10(6): 1355-1358.
  • 9Delbaere A, Bergmann PJ, Gervy-Decoster C, et al. Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome. Hum Reprod, 1997, 12(2): 236- 240.
  • 10Tamarat R, Silvestre IS, Durie M, et al. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor-and inflammation related pathways. Lab Invest, 2002, 82(6): 747-756.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部